Used in bone metabolism research to measure type I collagen degradation, this ELISA kit quantifies CTXI levels in biological samples such as serum or urine. It is widely applied in preclinical and clinical studies to assess bone resorption, particularly in osteoporosis, metabolic bone diseases, and cancer-related bone disorders. The assay helps evaluate the effectiveness of antiresorptive therapies like bisphosphonates or denosumab by monitoring changes in bone turnover markers. Its high sensitivity allows detection of early bone loss in conditions such as menopause, rheumatoid arthritis, or prolonged immobilization. Commonly used in pharmaceutical development and biomedical research to support diagnosis and treatment monitoring.